Nektar Therapeutics (NKTR) Director Greer R Scott Receives RSU Award

What Happened Greer R. Scott, a director of Nektar Therapeutics (NKTR), was granted a total of 6,000 restricted stock units (RSUs) on September 23, 2026. The filing shows 2,000 shares reported as common stock acquired at $0.00 and 4,000 reported as a derivative award at $0.00 (total reported cash value $0 on the Form 4). These are awards/vested-right grants (not open-market purchases or sales).

Key Details

• Transaction date (Period of Report): September 23, 2026; Form 4 filed September 25, 2026 (appears timely).
• Reported entries: 2,000 shares @ $0.00 (acquired — RSU) and 4,000 shares @ $0.00 (acquired — derivative RSU).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes of note:
  • F1: Each RSU represents a contingent right to receive one share upon vesting.
  • F2: The RSU award vests in full one year after September 23, 2026 (i.e., on/around Sept 23, 2027).
  • F3: All amounts have been adjusted for a 1-for-15 reverse stock split effective June 8, 2025.
  • F4: (Included in filing) references a stock option vesting in substantially equal monthly installments over the one-year period beginning Sept 23, 2026.
• No sale, cash exercise, or tax-withholding sale is reported here — this is an equity award grant.

Context RSUs are compensation awards that convert to shares only upon vesting; they are not immediate purchases or liquidity events and therefore do not directly signal buying or selling by the insider. The derivative notation simply indicates the award is a contingent/derivative right (RSU/option) rather than an immediate issuance of common shares. Because the filing shows $0 price per unit (standard for RSU grants), no immediate cash value is reported on the Form 4 itself.